JP2008508253A5 - - Google Patents

Download PDF

Info

Publication number
JP2008508253A5
JP2008508253A5 JP2007523167A JP2007523167A JP2008508253A5 JP 2008508253 A5 JP2008508253 A5 JP 2008508253A5 JP 2007523167 A JP2007523167 A JP 2007523167A JP 2007523167 A JP2007523167 A JP 2007523167A JP 2008508253 A5 JP2008508253 A5 JP 2008508253A5
Authority
JP
Japan
Prior art keywords
ccr2
therapeutic
administering
therapeutic agent
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007523167A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008508253A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2005/002162 external-priority patent/WO2006013427A2/en
Publication of JP2008508253A publication Critical patent/JP2008508253A/ja
Publication of JP2008508253A5 publication Critical patent/JP2008508253A5/ja
Withdrawn legal-status Critical Current

Links

JP2007523167A 2004-07-30 2005-07-18 Ccr2を介した疾患又は障害の治療法 Withdrawn JP2008508253A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59268304P 2004-07-30 2004-07-30
PCT/IB2005/002162 WO2006013427A2 (en) 2004-07-30 2005-07-18 Treatment of ccr2 mediated diseases or disorders

Publications (2)

Publication Number Publication Date
JP2008508253A JP2008508253A (ja) 2008-03-21
JP2008508253A5 true JP2008508253A5 (cg-RX-API-DMAC10.html) 2008-08-14

Family

ID=35207829

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007523167A Withdrawn JP2008508253A (ja) 2004-07-30 2005-07-18 Ccr2を介した疾患又は障害の治療法

Country Status (14)

Country Link
US (1) US20090196823A1 (cg-RX-API-DMAC10.html)
EP (1) EP1778285A2 (cg-RX-API-DMAC10.html)
JP (1) JP2008508253A (cg-RX-API-DMAC10.html)
KR (1) KR20080044360A (cg-RX-API-DMAC10.html)
CN (1) CN101005855A (cg-RX-API-DMAC10.html)
AU (1) AU2005268545A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0513953A (cg-RX-API-DMAC10.html)
CA (1) CA2575612A1 (cg-RX-API-DMAC10.html)
IL (1) IL180675A0 (cg-RX-API-DMAC10.html)
MX (1) MX2007001204A (cg-RX-API-DMAC10.html)
NO (1) NO20070996L (cg-RX-API-DMAC10.html)
RU (1) RU2007103332A (cg-RX-API-DMAC10.html)
WO (1) WO2006013427A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200700823B (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7671062B2 (en) 2006-07-28 2010-03-02 Bristol-Myers Squibb Company Modulators of chemokine receptor activity, crystalline forms and process
US7687508B2 (en) 2006-07-28 2010-03-30 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
US7629351B2 (en) 2006-07-28 2009-12-08 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino) pyrrolidin-1-yl)cyclohexyl)acetamide and other modulators of chemokine receptor activity, crystalline forms and process
CN102239180B (zh) * 2008-08-18 2014-12-31 辉瑞大药厂 抗ccr2抗体
US8383812B2 (en) 2009-10-13 2013-02-26 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
US9726666B2 (en) 2011-06-13 2017-08-08 Tla Targeted Immunotherapies Ab Diagnosing and treating inflammatory diseases
DK2723360T3 (en) * 2011-06-27 2017-08-28 Univ Pierre Et Marie Curie Paris 6 CCR2 antagonist peptides
WO2022235440A1 (en) * 2021-04-21 2022-11-10 The United States Government As Represented By The Department Of Veterans Affairs Method for treating traumatic brain injury, spinal cord injury, or stroke using small molecule inhibitors of ccr2

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312689B1 (en) * 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
FR2792837B1 (fr) * 1999-04-29 2001-07-13 Centre Nat Rech Scient Medicaments utiles pour le traitement des troubles de la regulation de la masse adipeuse et des maladies associees aux troubles de la production de leptine
US20050245537A1 (en) * 2002-04-24 2005-11-03 Noboru Tsuchimori Use of compounds having ccr antagonism
US20060183731A1 (en) * 2003-07-15 2006-08-17 Min Ge 7 and 8 membered heterocyclic cyclopentyl benzylamide modulators of chemokine receptor activity
CA2550596C (en) * 2003-12-18 2011-03-15 Incyte Corporation 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors

Similar Documents

Publication Publication Date Title
JP2008501776A5 (cg-RX-API-DMAC10.html)
EA200801071A1 (ru) Способы и композиции для применения в целях лечения пациентов с положительным по аутоантителам заболеванием
SG171648A1 (en) Use of dpp-iv inhibitors
NZ595262A (en) Use of il-23 and il-27 antagonists to treat autoimmune ocular inflammatory disease
DE602005018763D1 (de) Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität
WO2009021521A3 (en) Use of gaboxadol for the manufacture of a medicament for treating stress-mediated depression
RU2012124268A (ru) Бензимидазольные соединения и их применения
EA200700214A1 (ru) Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией
WO2004039325A3 (en) Treatment of pain with jnk inhibitors
JP2023531675A5 (cg-RX-API-DMAC10.html)
JP2004517824A5 (cg-RX-API-DMAC10.html)
Ren et al. Effect of intermittent pneumatic compression with different inflation pressures on the distal microvascular responses of the foot in people with type 2 diabetes mellitus
RU2008116567A (ru) Биомаркеры
Huang et al. Acupuncture stimulation of ST‐36 (Zusanli) significantly mitigates acute lung injury in lipopolysaccharide‐stimulated rats
NO20055531L (no) Preparat for forbedret kognisjon og hukommelse
RU2007103332A (ru) Способы лечения опосредуемых ccr2 заболеваний или нарушений
RU2013112890A (ru) Терапевтическое применение 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазина
MX2009004646A (es) Agente que comprende g-csf para la prevencion y el tratamiento de la neuropatia periferica diabetica.
ATE487480T1 (de) Perhexilin zur behandlung von chronischer herzinsuffizienz
Yong et al. Electroacupuncture pretreatment attenuates brain injury in a mouse model of cardiac arrest and cardiopulmonary resuscitation via the AKT/eNOS pathway
ZHANG et al. Efficacy of acupuncture in combination with medicine for mild cognitive impairment after cerebral infarction: a randomized controlled trial
JP2004532389A5 (cg-RX-API-DMAC10.html)
Komatsuzaki et al. Suppression of osteopontin functions by levocetirizine, a histamine H1 receptor antagonist, in vitro
EP1804789A4 (en) METHOD FOR TREATING PREECLAMPSY IN HUMANS WITH RESIBUFAGENIN
FR2871800B1 (fr) Sel de sodium monohydrate du s-tenatoprazole et application en therapeutique